Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan

Akihiro Nishie; Satoshi Goshima; Hiroki Haradome; Etsuro Hatano; Yasuharu Imai; Masatoshi Kudo; Masanori Matsuda; Utaroh Motosugi; Satoshi Saitoh; Kengo Yoshimitsu; Bruce Crawford; Eliza Kruger; Graeme Ball; Hiroshi Honda

doi:10.1016/j.clinthera.2017.03.006

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Masahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, Shuichi Kaneko, Mie Azuma, Ronda Copher, Genevieve Meier, Janice Pan, Mika Ishii, Shunya Ikeda

Article2018

PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN

Shunya Ikeda, Masatoshi Kudo, Namiki Izumi, Satoshi Kaneko, Masahiro Kobayashi, Mie Azuma, Ronda Copher, Suchin Virabhak, David Mitchell, Genevieve Meier, Mika Ishii

Editorial Material2023

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan

Masatoshi Kudo

Article2023

198P Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan

Namiki Izumi, Masatoshi Kudo, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yutaka Kondo, Kazuhisa Yabushita, K Motoyoshi, Junji Furuse

Article2002

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Josep M. Llovet

Gut